New hope for transplant patients: safer virus prevention?
NCT ID NCT06001320
Summary
This study compares two drugs used to prevent CMV, a common and serious viral infection, in African American kidney transplant patients. Researchers want to see if a newer drug called letermovir works as well as the standard drug valganciclovir but causes fewer side effects, particularly low white blood cell counts. The trial involves 60 participants who will take one of the drugs for six months after their transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
VCU Medical Center
Richmond, Virginia, 23219, United States
Conditions
Explore the condition pages connected to this study.